ProQR Therapeutics (NASDAQ:PRQR) Director Purchases $258,000.00 in Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius acquired 150,000 shares of the stock in a transaction on Friday, July 17th. The stock was bought at an average price of $1.72 per share, with a total value of $258,000.00. Following the transaction, the director directly owned 300,000 shares in the company, valued at approximately $516,000. This represents a 100.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bart Filius also recently made the following trade(s):

• On Friday, June 26th, Bart Filius bought 150,000 shares of ProQR Therapeutics stock. The shares were bought at an average price of $1.54 per share, for a total transaction of $231,000.00.

ProQR Therapeutics Price Performance

PRQR opened at $1.78 on Friday. ProQR Therapeutics N.V. has a one year low of $1.33 and a one year high of $3.10. The company’s 50 day simple moving average is $1.67 and its 200-day simple moving average is $1.64. The stock has a market capitalization of $187.55 million, a P/E ratio of -3.56 and a beta of 0.04.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. As a group, analysts anticipate that ProQR Therapeutics N.V. will post -0.52 EPS for the current year.

Institutional Trading of ProQR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. lifted its stake in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the period. Guggenheim Capital LLC acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth $35,000. Moody Lynn & Lieberson LLC acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth $50,000. Invesco Ltd. bought a new stake in ProQR Therapeutics in the fourth quarter valued at about $51,000. Finally, Axiom Investment Management LLC bought a new stake in ProQR Therapeutics in the first quarter valued at about $53,000. Institutional investors own 32.65% of the company’s stock.

Analysts Set New Price Targets

PRQR has been the subject of a number of recent research reports. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Weiss Ratings cut ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Chardan Capital lowered their price objective on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 26th. JonesTrading dropped their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Finally, Wall Street Zen downgraded shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.